Polymer Factory (POLYMER) Q2 2026 earnings summary

Executive summary

• Strong interest from international organizations and new commercial collaborations with multinational companies in Q2 2026.

• Strategic collaboration initiated with Thermo Fisher Scientific for SpheriCal® technology.

• Participation in major industry events and sponsorship of upcoming symposiums to boost visibility.

• Dendritic Nanogels (DNG) show promising results in drug delivery research for challenging cancers.

Financial highlights

• Net sales for Q2 2026 were KSEK 419, down 53% year-over-year; H1 2026 net sales were KSEK 722, down 42%.

• Loss for Q2 2026 was KSEK -451 (vs. -165 in Q2 2025); H1 2026 loss was KSEK -1,796 (vs. -1,045 in H1 2025).

• Cash and bank at June 30, 2026: KSEK 1,706; equity: KSEK 4,606.

• Cash flow from operating activities for H1 2026 was KSEK -2,284.

• Board notes risk of insufficient financing over the next 12 months if sales or cost reductions do not improve.

Outlook and guidance

• Encouraging commercial momentum despite macroeconomic and geopolitical challenges.

• Continued focus on strategic partnerships and product innovation to drive long-term growth.